Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 1/2 5Phase 2 4Phase 3 2Phase 4 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 502Urinary Bladder Neoplasms 139Carcinoma, Renal Cell 116Neoplasms 66Kidney Neoplasms 53Non-Muscle Invasive Bladder Neoplasms 43Neoplasm Metastasis 38Carcinoma, Transitional Cell 38Breast Neoplasms 30Testicular Neoplasms 28Recurrence 20Wilms Tumor 18Parkinson Disease 4, Autosomal Dominant Lewy Body 14Pain 13Ovarian Neoplasms 13Urologic Neoplasms 12Testicular Germ Cell Tumor 12Teratoma 12Seminoma 12Multiple Myeloma 12Burkitt Lymphoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Large B-Cell, Diffuse 11Carcinoma, Ovarian Epithelial 11Carcinoma 11Urogenital Neoplasms 10Neuroblastoma 10Lymphoma, Non-Hodgkin 10Lymphoma, Mantle-Cell 10Lymphoma, Large-Cell, Immunoblastic 10

Interventions

Abiraterone Acetate 2rucaparib 1enzalutamide 1Prednisone 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Metastatic Castration Resistant Prostate Cancer × Genitourinary × Clear all
NCT02975934 2025-07-25

TRITON3

pharmaand GmbH

Phase 3 Completed
405 enrolled 34 charts 1 FDA
Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT04056754 2019-08-14

Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Completed
268 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡